Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.
2.

Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.

Wade M, Baker FJ, Roscigno R, DellaMaestra W, Arneson CP, Hunt TL, Lai AA.

J Clin Pharmacol. 2004 May;44(5):503-9.

PMID:
15102871
3.

Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.

Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA.

J Clin Pharmacol. 2004 Jan;44(1):83-8.

PMID:
14681345
4.

Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin.

Wade M, Hunt TL, Lai AA.

J Cardiovasc Pharmacol. 2003 Jun;41(6):908-15.

PMID:
12775969
5.

Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.

McSwain CS, Benza R, Shapiro S, Hill N, Schilz R, Elliott CG, Zwicke DL, Oudiz RJ, Staszewski JP, Arneson CP, Wade M, Zaccardelli D, McLaughlin V.

J Clin Pharmacol. 2008 Jan;48(1):19-25.

6.

The role of treprostinil in the management of pulmonary hypertension.

Skoro-Sajer N, Lang I.

Am J Cardiovasc Drugs. 2008;8(4):213-7.

PMID:
18690755
7.

Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.

Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette Ld, Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie N.

J Cardiovasc Pharmacol. 2007 Jan;49(1):1-5.

PMID:
17261956
8.
9.

Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.

Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K.

J Clin Pharmacol. 2010 Jul;50(7):829-34. doi: 10.1177/0091270009351173.

PMID:
20133511
10.

Treprostinil for pulmonary hypertension.

Vachiéry JL, Naeije R.

Expert Rev Cardiovasc Ther. 2004 Mar;2(2):183-91. Review.

PMID:
15151467
11.

Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.

Jones A, Wang-Smith L, Pham T, Laliberte K.

J Cardiovasc Pharmacol. 2014 Mar;63(3):227-32. doi: 10.1097/FJC.0000000000000039.

PMID:
24603117
13.
14.

[Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].

Escribano Subías P, Cea-Calvo L, Tello de Menesses R, Gómez Sánchez MA, Delgado Jiménez JF, Sáenz de la Calzada C.

Rev Esp Cardiol. 2003 Aug;56(8):818-21. Spanish.

15.

Treprostinil for the treatment of pulmonary hypertension.

Skoro-Sajer N, Lang I.

Expert Opin Pharmacother. 2008 Jun;9(8):1415-20. doi: 10.1517/14656566.9.8.1415 . Review.

PMID:
18473715
16.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
17.
18.

Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.

Metz DC, Devlin JW, Vakily M, Atkinson S, Lloyd E.

Pharmacotherapy. 2008 Mar;28(3):301-7. doi: 10.1592/phco.28.3.301.

PMID:
18294109
19.

Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease.

Sakai T, Planinsic RM, Mathier MA, de Vera ME, Venkataramanan R.

Transpl Int. 2009 May;22(5):554-61. doi: 10.1111/j.1432-2277.2008.00830.x.

20.

Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.

Tapson VF, McLaughlin VV, Gomberg-Maitland M, Widlitz AC, Krichman AD, Laliberte KJ, Zaccardelli DS, Barst RJ.

J Vasc Access. 2006 Jul-Sep;7(3):112-7.

PMID:
17019662

Supplemental Content

Support Center